Clinical trial
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and…
NCT00038831 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038831 |
|---|---|
| Title | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS |
| Official title | Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | Mylotarg, Fludarabine, Melphalan, Anti-thymocyte globulin, Stem cell transplant |
| Enrollment | 47 |
| Start date | May 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Jun 7, 2002 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: